Zilebesiran and IONIS-AGT-LR are novel RNA-based therapeutics that target angiotensinogen (AGT) synthesis in the liver, representing a possible shift in the management of hypertension in OSA, a phenotype characterized by RAAS hyperactivation, nocturnal hypertension, and aldosterone excess. This evidence concerns the gene AGT and hypertensive disorder.